News from eli lilly and company; boehringer ingelheim pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 17, 2014, 15:53 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: Boehringer Ingelheim and Eli Lilly and Company announce resubmission of New Drug Application for empagliflozin to FDA

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the resubmission of a New Drug...

May 15, 2014, 12:45 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Type 2 diabetes: findings presented from retrospective analysis of pooled data examining linagliptin in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed...

Apr 14, 2014, 09:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Boehringer Ingelheim and Eli Lilly and Company Announce New Drug Application Filing in the U.S. for the Combination Tablet of Empagliflozin and Linagliptin

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration...

Mar 05, 2014, 09:30 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

U.S. Food and Drug Administration Issues Complete Response Letter for Empagliflozin

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug...

Jul 31, 2013, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced enrollment of the first patient into...

Jun 22, 2013, 11:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Phase III data show investigational compound empagliflozin significantly reduced blood glucose in adults with type 2 diabetes

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced two late-breaking presentations with results...

Jun 22, 2013, 11:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results of two phase III 24-week clinical...

Jun 22, 2013, 11:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Phase III studies show linagliptin improved blood glucose control in Asian adults with type 2 diabetes

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two phase III clinical studies...

Jun 22, 2013, 11:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Phase III study finds investigational agent empagliflozin significantly reduced blood glucose in adults with type 2 diabetes and impaired kidney function

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results of a 52-week phase III clinical trial of...

Jun 22, 2013, 11:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Results of new exploratory analyses assessing the incidence of hypoglycemia with linagliptin in adults with type 2 diabetes announced

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two exploratory analyses assessing...

Jun 22, 2013, 11:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Phase III data show significant reductions in blood glucose with investigational compound empagliflozin used as monotherapy in adults with type 2 diabetes

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results of a 24-week phase III clinical...

Jun 22, 2013, 11:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

New data about the safety and efficacy of linagliptin in adults with type 2 diabetes who have moderate to severe renal impairment presented at ADA

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from a new study in which...

Jun 22, 2013, 11:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Phase III data show investigational compound empagliflozin plus insulin significantly reduced HbA1c in adults with type 2 diabetes

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results of a 78-week phase III clinical...

Jun 20, 2013, 11:04 ET
Jun 13, 2013, 14:34 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

 Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) support the American Diabetes Association (ADA) call...

Jun 11, 2013, 08:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Boehringer Ingelheim and Eli Lilly and Company Alliance to Feature 34 Presentations on Type 1 and Type 2 Diabetes at the 73rd American Diabetes Association Scientific Sessions®

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) are pleased to announce that the companies' diabetes...

May 02, 2013, 08:00 ET
Boehringer Ingelheim logo.  (PRNewsFoto/Eli Lilly and Company)

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company launch educational campaign about emerging science in type 2 diabetes

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the launch of an educational campaign...

Mar 19, 2013, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Boehringer Ingelheim and Lilly initiate MARLINA clinical trial to evaluate use of Tradjenta® (linagliptin) tablets in patients with type 2 diabetes and albuminuria

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the initiation of a Phase IIIb trial to...

Nov 08, 2012, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Cardiovascular outcome study on Tradjenta® (linagliptin) tablets in adult patients with type 2 diabetes completes enrollment

 Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the clinical trial enrollment of patients...

Sep 13, 2012, 08:00 ET
Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announce the availability of a new online program offering...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge